Nifty
Sensex
:
:
15746.45
52578.76
-78.00 (-0.49%)
-316.65 (-0.60%)

Pharmaceuticals & Drugs - Global

Rating :
44/99

BSE: 532296 | NSE: GLENMARK

588.75
27-Jul-2021
  • Open
  • High
  • Low
  • Previous Close
  •  635.50
  •  635.50
  •  585.05
  •  626.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5778251
  •  34904.43
  •  690.95
  •  419.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,628.17
  • 17.14
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,385.56
  • 0.42%
  • 2.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.63%
  • 1.19%
  • 14.42%
  • FII
  • DII
  • Others
  • 26.82%
  • 9.15%
  • 1.79%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.69
  • 7.07
  • 5.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 3.39
  • 1.00

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.53
  • 0.87
  • -1.17

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.83
  • 16.65
  • 15.55

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.68
  • 3.20
  • 2.32

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.58
  • 10.82
  • 9.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
2,859.90
2,767.49
3.34%
2,786.76
2,735.56
1.87%
2,952.48
2,815.04
4.88%
2,344.79
2,322.88
0.94%
Expenses
2,336.47
2,301.80
1.51%
2,256.69
2,295.49
-1.69%
2,399.67
2,364.63
1.48%
1,866.72
1,980.97
-5.77%
EBITDA
523.43
465.69
12.40%
530.07
440.08
20.45%
552.81
450.41
22.73%
478.07
341.91
39.82%
EBIDTM
18.30%
16.83%
19.02%
16.09%
18.72%
16.00%
20.39%
14.72%
Other Income
8.49
44.14
-80.77%
15.09
32.96
-54.22%
-31.88
80.83
-
58.51
1.67
3,403.59%
Interest
83.33
98.47
-15.38%
95.41
96.06
-0.68%
80.63
89.77
-10.18%
93.74
93.02
0.77%
Depreciation
111.07
126.28
-12.04%
115.20
106.00
8.68%
104.07
94.16
10.52%
113.22
90.73
24.79%
PBT
337.51
317.96
6.15%
347.97
270.98
28.41%
339.38
347.30
-2.28%
357.61
159.83
123.74%
Tax
103.65
97.65
6.14%
99.79
80.14
24.52%
105.38
91.76
14.84%
103.57
50.55
104.89%
PAT
233.87
220.31
6.15%
248.18
190.84
30.05%
233.99
255.54
-8.43%
254.04
109.28
132.47%
PATM
8.18%
7.96%
8.91%
6.98%
7.93%
9.08%
10.83%
4.70%
EPS
8.29
7.81
6.15%
8.80
6.76
30.18%
8.29
9.06
-8.50%
9.00
3.87
132.56%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
Net Sales Growth
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
 
Cost Of Goods Sold
3,698.82
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
Gross Profit
7,245.11
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
GP Margin
66.20%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
Total Expenditure
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
Power & Fuel Cost
-
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
% Of Sales
-
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
Employee Cost
-
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
% Of Sales
-
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
Manufacturing Exp.
-
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
% Of Sales
-
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
General & Admin Exp.
-
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
% Of Sales
-
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
Selling & Distn. Exp.
-
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
% Of Sales
-
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
Miscellaneous Exp.
-
47.19
33.29
314.55
88.52
38.82
38.48
228.40
33.61
0.00
0.00
% Of Sales
-
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
EBITDA
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
EBITDA Margin
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
Other Income
50.21
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
Interest
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
Depreciation
443.56
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
PBT
1,382.47
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
Tax
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
Tax Rate
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
PAT
970.08
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
PAT before Minority Interest
970.08
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
Minority Interest
0.00
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
PAT Margin
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
PAT Growth
25.02%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
 
EPS
34.38
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31
16.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
Share Capital
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
Total Reserves
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
Non-Current Liabilities
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
Unsecured Loans
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
Current Liabilities
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
Trade Payables
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
Other Current Liabilities
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
Short Term Borrowings
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
Short Term Provisions
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
Total Liabilities
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
Net Block
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
Gross Block
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
Accumulated Depreciation
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
Non Current Assets
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
Capital Work in Progress
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
Non Current Investment
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
Other Non Current Assets
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
Current Assets
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
Sundry Debtors
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
Cash & Bank
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
Other Current Assets
1,147.78
765.22
810.78
683.39
986.77
774.38
872.81
635.91
593.95
465.11
Short Term Loans & Adv.
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
Net Current Assets
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
Total Assets
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
PBT
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
Adjustment
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
Changes in Working Capital
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
Cash after chg. in Working capital
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
Net Fixed Assets
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
Net Investments
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
Others
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
Cash from Financing Activity
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
Net Cash Inflow / Outflow
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
Opening Cash & Equivalents
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
Closing Cash & Equivalent
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
ROA
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
ROE
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
ROCE
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
Fixed Asset Turnover
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
Receivable days
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
Inventory Days
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
Payable days
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
Cash Conversion Cycle
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
Total Debt/Equity
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
Interest Cover
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00

News Update:


  • Glenmark Pharmaceuticals to conduct phase III trial on nasal spray
    9th Jul 2021, 11:25 AM

    The company had sought emergency approval for import and marketing of the nasal spray from the drug regulator last week

    Read More
  • Glenmark gets USFDA’s tentative approval for Nintedanib Capsules
    25th Jun 2021, 09:08 AM

    Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark gets USFDA’s nod for Arformoterol Tartrate Inhalation Solution
    23rd Jun 2021, 09:17 AM

    The BROVANA Inhalation Solution, 15 mcg/2 mL market achieved annual sales of around $437.9 million

    Read More
  • Glenmark launches Tiotropium Bromide Dry Powder Inhaler in UK
    15th Jun 2021, 09:53 AM

    COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult

    Read More
  • Glenmark gets USFDA’s nod for Theophylline Extended-Release Tablets
    4th Jun 2021, 09:06 AM

    The company has been granted a competitive generic therapy designation for Theophylline Extended-Release Tablets USP, 450 mg

    Read More
  • Glenmark Pharmaceuticals launches Rufinamide Tablets
    1st Jun 2021, 09:19 AM

    Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark Pharma reports 6% rise in Q4 consolidated net profit
    29th May 2021, 10:29 AM

    Total consolidated income of the company increased by 2.02% at Rs 2868.39 crore for Q4FY21

    Read More
  • Glenmark Pharma receives USFDA’s nod for Icatibant Injection
    24th May 2021, 09:56 AM

    Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA

    Read More
  • Glenmark launches Ryaltris-AZ at affordable price in India
    3rd May 2021, 09:27 AM

    This will provide patients a far more convenient, cost effective treatment option in the country

    Read More
  • Glenmark Pharma to launch nasal spray Ryaltris in EU
    26th Apr 2021, 13:16 PM

    Ryaltris is now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.